Physician profile
Jorge Barrero
NPI 1962450346
$9,775.85
in general payments reported to CMS, 2019-2025
36 companies · $1,210 in 2025
The $1,210 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $661 · 2021: $1,631 · 2022: $2,046 · 2023: $1,640 · 2024: $1,416 · 2025: $1,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,216 · Education: $49.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,215.91 |
| Education | $49.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,346.99 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $1,285.04 | 2019-2025 | Rayaldee |
| Amgen INC. | $899.00 | 2019-2024 | Krystexxa |
| Vifor Pharma, INC. | $644.91 | 2019-2025 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $643.78 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $602.40 | 2021-2024 | |
| Travere Therapeutics, INC. | $507.93 | 2022-2025 | Filspari |
| Akebia Therapeutics INC | $444.67 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $371.20 | 2020-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $299.89 | 2019-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $295.09 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $245.38 | 2019-2024 | Velphoro |
| Baxter Healthcare | $238.77 | 2019-2023 | Renal - Pd |
| Ardelyx, INC. | $209.27 | 2023-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $204.41 | 2020-2024 | Jesduvroq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $179.10 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.89 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $157.91 | 2024-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $150.20 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $147.26 | 2021-2025 | Lupkynis |
| Bard Peripheral Vascular, INC. | $138.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $108.06 | 2019 | |
| Shield Therapeutics INC | $83.20 | 2023-2025 | Accrufer |
| Shire North American Group INC | $52.81 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $47.68 | 2023 | |
| Pfizer INC. | $45.63 | 2024-2025 | |
| Medtronic, INC. | $42.78 | 2023 | |
| Idorsia Pharmaceuticals US INC | $37.34 | 2024 | Quviviq |
| Vantive US Healthcare LLC | $30.62 | 2025 | Renal - Pd |
| Alnylam Pharmaceuticals INC. | $28.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $22.69 | 2019 | |
| Genzyme Corporation | $21.86 | 2019 | |
| Lilly USA, LLC | $21.26 | 2025 | Zepbound |
| Paratek Pharmaceuticals, INC. | $20.86 | 2020 | |
| Cormedix INC. | $19.54 | 2025 | Defencath |
| Cumberland Pharmaceuticals, INC. | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Barrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.